查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008668

子宮內避孕器市場：按產品類型、使用時長、銷售管道和最終用戶分類的全球市場預測 – 2026-2032 年

Intrauterine Devices Market by Device Type, Usage Duration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，子宮內避孕器 (IUD) 市值將達到 33.7 億美元，到 2026 年將成長至 35 億美元，到 2032 年將達到 49.6 億美元，複合年成長率為 5.68%。

主要市場統計數據
基準年 2025 33.7億美元
預計年份：2026年 35億美元
預測年份 2032 49.6億美元
複合年成長率 (%) 5.68%

本報告對避孕器）在現代避孕策略中的作用進行了清晰權威的概述，並闡述了本報告的分析方法和價值。

子宮內避孕器（IUD）是現代避孕策略的基石，它提供長效且可逆的避孕效果，符合不斷變化的患者偏好和臨床指南。圍繞這些技術的格局已不再局限於簡單的銅製與激素二元對立，而是涵蓋了裝置設計、放置技術和術後護理通訊協定等方面的進步。臨床醫生、保險公司和製造商都必須應對日益複雜的臨床證據、監管、供應鏈趨勢和以患者為中心的服務模式之間的相互作用。

對技術創新、監管重點以及不斷變化的患者和醫療保健提供者的偏好如何重塑子宮內避孕器(避孕器)的引入和使用進行詳細分析。

子宮內避孕器（避孕器）的現狀正經歷著變革，這主要得益於技術進步、臨床指南的更新以及患者期望的轉變。荷爾蒙配方和節育器形狀的創新正在延長放置時間窗口並提高耐受性。此外，臨床醫師對產後和青少年放置節育器的理解不斷加深，也擴大了適用人群。同時，遠端醫療和數位化服務的進步正在重塑放置前諮詢和追蹤流程，從而建立以患者為中心的模式，減輕診所的負擔並提高患者對建議追蹤計畫的依從性。

評估 2025 年的關稅環境以及貿易政策變化對避孕器(IUD) 供應鏈的韌性、採購選擇和臨床可用性的影響。

2025年關稅的實施和貿易政策的調整為整個子宮內避孕器供應鏈帶來了新的變數，影響了製造成本、分銷計劃和籌資策略。進口零件和原料的關稅增加了部分製造商的單位投入成本，促使他們採取短期應對措施，例如與供應商重新談判合約、策略性地增加庫存以及選擇性地轉移某些生產活動。這些供應側的調整凸顯了彈性籌資策略的重要性，這些策略需要平衡成本、前置作業時間和品質保證要求。

透過對設備類型、通路、臨床環境和計畫使用週期進行詳細的細分分析，可以製定有針對性的策略和營運方案。

分析細分市場層面的趨勢揭示了醫療器材採納和採購過程中存在的細微因素，這些因素會因醫療設備的特性、通路、終端用戶環境和預期使用壽命而異。根據醫療設備的產品類型，銅製器械和激素類器械的市場研究是分開進行的。這種區分仍然是臨床諮詢和產品選擇的關鍵決定因素，因為它對應著不同的副作用、非避孕益處以及對荷爾蒙過敏患者的適用性。當需要避免使用荷爾蒙或月經管理並非主要考慮因素時，銅製器械仍然是首選。另一方面，尋求減少出血或月經益處的患者通常更傾向於選擇荷爾蒙類器械。

詳細的區域分析表明，基礎設施、報銷制度和文化因素如何獨特地影響子宮內避孕器( IUD) 的分銷和商業性方法。

子宮內避孕器（ IUD）的使用和商業策略的區域趨勢反映了醫療基礎設施、報銷標準以及對避孕的文化態度方面的差異。在美洲，長效可逆避孕法正日益融入婦科和產科的常規工作流程，尤其注重產後放置，並擴大了醫護人員的培訓計畫。該地區的需求模式受到公共和私人保險公司、都市區醫療服務獲取差異以及影響醫療系統層面覆蓋範圍和採購的積極政策辯論等因素的影響。

對競爭定位進行策略概述，闡述臨床證據、醫療保健專業人員的支持和經銷夥伴關係如何塑造避孕器(IUD) 領域的長期領導地位。

領先的醫療器材製造商與新興挑戰者之間的競爭格局日益取決於臨床差異化、分銷靈活性以及對循證醫學的投入。那些兼具明確臨床優勢、可靠的上市後數據以及強大的醫療專業人員支援計畫的公司，通常能夠更深入地融入醫療服務系統。與藥房、醫院系統和培訓聯盟建立策略合作夥伴關係，有助於解決與植入技術、庫存管理和患者追蹤相關的實際障礙，從而促進產品的推廣應用。

製造商和相關人員提出切實可行的、有影響力的建議，以增強供應鏈韌性、證據生成、臨床醫生培訓以及患者跨管道獲取醫療服務。

產業領導者應優先採取一系列切實有效的措施，以維持市場准入、維護臨床信任並打造差異化價值提案。首先，應透過多元化零件採購管道並確保檢驗的替代供應商，增強價值鏈韌性，從而減輕關稅相關干擾和其他供應鏈中斷的影響。除了這種營運柔軟性之外，還應制定清晰的監管藍圖，對替代製造地和原料進行認證，以避免臨床供應缺口。

對調查來源、證據檢驗和調查方法進行透明的解釋，以整合子宮內避孕器的臨床、監管和供應鏈見解。

本分析基於多方面的研究途徑，整合了同行評審的臨床文獻、監管申報文件、醫療設備附加檔、臨床專家訪談以及對供應鏈和政策趨勢的系統性回顧。臨床研究結果是基於隨機對照試驗、觀察性隊列研究和縱向安全性註冊研究，這些研究均經過調查方法嚴謹性和與當代臨床實踐相關性的評估。監管文件，包括核准文件和上市後監控總結，均經過仔細審查，以識別影響產品生命週期管理的新興合規趨勢和安全訊號。

簡明結論整合了臨床進步、供應韌性和有針對性的市場策略如何共同決定避孕器(IUD) 的未來供應和市場定位。

避孕器（IUD）目前正處於一個轉折點，臨床創新、不斷發展的醫療服務模式以及貿易政策因素在此交匯，既帶來了機遇，也帶來了挑戰。技術進步和臨床接受度的提高，尤其是在產後即刻和青春期放置方面，正使這些裝置在綜合生殖健康策略中發揮越來越重要的作用。同時，供應鏈對關稅和零件採購的脆弱性凸顯了營運彈性以及製造、監管和採購部門之間更緊密協調的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：子宮內避孕器市場：依器械類型分類

  • 由銅製成
  • 荷爾蒙藥物

第9章：依使用時長分類的子宮內避孕器市場

  • 5年或以上
  • 3-5年
  • 不到3年

第10章：子宮內避孕器市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：子宮內避孕器市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章：子宮內避孕器市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：子宮內避孕器市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：子宮內避孕器市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國子宮內避孕器市場

第16章：中國子宮內避孕器市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • BioFem Therapeutics, LLC
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CooperCompanies, Inc.
  • Gedeon Richter Plc.
  • Medicines360, Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Mona Lisa NV
  • Mylan NV by Viatris Inc.
  • Novartis AG
  • Ocon Medical Ltd
  • Pregna International Ltd.
  • Prosan International BV
  • Searchlight Pharma Inc.
  • Shenzhen Salubris Pharmaceuticals Co., Ltd.
Product Code: MRR-8E22B61932AA

The Intrauterine Devices Market was valued at USD 3.37 billion in 2025 and is projected to grow to USD 3.50 billion in 2026, with a CAGR of 5.68%, reaching USD 4.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.37 billion
Estimated Year [2026] USD 3.50 billion
Forecast Year [2032] USD 4.96 billion
CAGR (%) 5.68%

A clear and authoritative introduction situating intrauterine devices within modern contraceptive strategy and outlining the report's analytical approach and value

Intrauterine devices represent a cornerstone of modern contraceptive strategy, offering long-acting, reversible protection that aligns with evolving patient preferences and shifting clinical guidelines. The landscape surrounding these technologies has broadened beyond a simple copper versus hormonal dichotomy to encompass advances in device design, insertion techniques, and post-insertion care protocols. Clinicians, payers, and manufacturers alike must navigate an increasingly complex interplay of clinical evidence, regulatory scrutiny, supply chain dynamics, and patient-centered access models.

This executive summary synthesizes cross-cutting developments that are redefining how intrauterine devices are perceived, selected, and delivered across care settings. It situates recent technological refinements within real-world adoption patterns and operational constraints, highlighting the implications for training, procurement, and stakeholder communications. Readers will find a focused narrative that connects clinical efficacy and safety considerations to pragmatic commercial and policy questions, thereby enabling more informed decisions about product portfolios, distribution partnerships, and provider engagement strategies.

The following sections move from high-level shifts and policy impacts to granular segmentation and regional nuances, culminating in prescriptive recommendations and an accessible explanation of the research methods underpinning the analysis. Each element prioritizes clarity and applicability so that health system leaders, device manufacturers, and commercial strategists can translate insight into measurable actions.

A detailed exploration of how technological innovation, regulatory focus, and evolving patient and care delivery preferences are reshaping intrauterine device adoption and use

The landscape for intrauterine devices is undergoing transformative shifts driven by technological refinement, evolving clinical guidelines, and changing patient expectations. Innovations in hormonal formulations and device geometries are expanding insertion windows and improving tolerability, while growing clinician familiarity with immediate postpartum and adolescent insertion is broadening the pool of appropriate candidates. At the same time, advances in telehealth and digital engagement have reconfigured pre-insertion counseling and follow-up pathways, enabling more patient-centered models that reduce clinic burden and increase adherence to recommended follow-up schedules.

Concurrently, regulatory attention to safety surveillance and post-market studies has intensified, prompting manufacturers to invest more heavily in real-world evidence generation. This emphasis on longitudinal safety monitoring has elevated the importance of traceability, device registries, and harmonized adverse event reporting processes. Procurement and distribution models are shifting as well: centralized hospital purchasing is coexisting with an expansion of online pharmacy fulfillment and a renewed focus on ensuring continuity of supply for outpatient settings. These distribution shifts are altering commercial dynamics and reshaping the nature of partnerships between manufacturers, pharmacies, and provider organizations.

Importantly, patient preferences are changing; there is a stronger demand for reversible, long-acting contraception that minimizes systemic side effects and fits diverse reproductive plans. This has intensified investment in product differentiation and patient education initiatives, as manufacturers and providers seek to match device attributes to individual needs. The combined effect of technological, regulatory, and behavioral change is a market that rewards clinical evidence, ease of use, and access, and that penalizes slow adaptation to new care delivery models.

An assessment of the 2025 tariff environment and how trade policy changes are affecting supply chain resilience, procurement choices, and clinical availability of intrauterine devices

The imposition of tariffs and trade policy adjustments in 2025 has introduced a new variable that affects manufacturing costs, distribution planning, and procurement strategies across the intrauterine device supply chain. Tariffs on imported components and raw materials have raised unit input costs for some manufacturers, prompting near-term operational responses such as renegotiated supplier contracts, strategic inventory build-up, and selective relocation of certain manufacturing activities. These supply-side adjustments underscore the importance of a flexible procurement strategy that balances cost, lead time, and quality assurance requirements.

From a distribution perspective, tariffs have encouraged greater attention to sourcing diversification and to the feasibility of onshoring critical manufacturing steps. Health systems and purchasing organizations are reassessing supplier risk profiles and contingency plans to mitigate disruptions. Regulatory timelines for certifying relocated manufacturing lines or alternative component suppliers can introduce delays, requiring proactive engagement with authorities to validate equivalence and maintain continuity of supply.

Clinicians and provider networks may experience practical impacts in the form of changes to product assortments and availability at the point of care, which necessitates clearer communication with patients about device options. Procurement teams should evaluate long-term contracts and consider multi-sourcing strategies that preserve clinical choice while managing exposure to tariff-related cost volatility. In sum, the 2025 tariff environment necessitates a strategic response that integrates supply chain resilience, regulatory planning, and transparent stakeholder communication to sustain access and protect clinical continuity.

A granular segmentation analysis connecting device type, distribution pathway, clinical setting, and intended duration to inform targeted strategy and operational alignment

Segment-level dynamics reveal nuanced drivers of adoption and procurement that vary by device characteristics, distribution pathways, end-user environments, and intended duration of use. Based on Device Type, market is studied across Copper and Hormonal, and this distinction remains a primary determinant of clinical counseling and product selection because it aligns with differing side-effect profiles, non-contraceptive benefits, and suitability for patients with hormone sensitivities. Copper devices continue to appeal where hormone avoidance is desired and where menstrual management is less of a primary concern, while hormonal devices are often prioritized for patients seeking lighter bleeding patterns and amenorrhea-related benefits.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, and each channel has unique implications for stock management, reimbursement navigation, and patient access models. Hospital pharmacies typically support immediate postpartum and inpatient insertion workflows and therefore prioritize on-hand availability and established clinician relationships. Online pharmacies are reshaping pre-procedure counseling and device procurement by facilitating remote ordering and discreet fulfillment, while retail pharmacies play a critical role in outpatient continuity and often bridge the gap between clinician recommendation and patient procurement.

Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, and the choice of end-user setting influences procedural protocols, training requirements, and device preference. Ambulatory surgical centers often emphasize efficiency and predictable device selection to streamline throughput, hospitals must balance inventory for both inpatient and outpatient insertion needs, and specialty clinics may focus on high-touch counseling and complex case management. Based on Usage Duration, market is studied across Over Five Years, Three To Five Years, and Under Three Years, and duration categories are central to product positioning, warranty and reimbursement conversations, and patient counseling. Long-duration devices align with goals of minimal maintenance and sustained efficacy, whereas shorter-duration options can appeal to patients seeking more frequent fertility planning or those trialing device tolerance.

Taken together, these segmentation lenses provide a framework for aligning clinical value propositions with distribution capabilities and end-user workflow requirements. Manufacturers and providers can leverage these insights to tailor messaging, optimize inventory placement, and design training that maps device attributes to specific clinical and operational contexts.

An in-depth regional synthesis showing how infrastructure, reimbursement frameworks, and cultural factors uniquely influence intrauterine device adoption and commercial approaches

Regional dynamics in intrauterine device utilization and commercial strategy reflect divergent healthcare infrastructures, reimbursement norms, and cultural attitudes toward contraception. In the Americas, clinical practice increasingly integrates long-acting reversible contraception into both routine gynecologic care and obstetric workflows, with a focus on immediate postpartum insertion and expanding provider training programs. Demand patterns in this region are shaped by a mix of public and private payers, variable access across rural and urban settings, and active policy discussions that influence coverage and procurement at the health system level.

In Europe, Middle East & Africa, the landscape is heterogeneous: established European markets emphasize rigorous post-market surveillance and incremental device innovation, while healthcare systems in parts of the Middle East and Africa face access constraints that prioritize cost-effective, robust supply chains and simplified training protocols. Stakeholders in this region must navigate a wide spectrum of regulatory pathways and health system maturity levels, which prompts differentiated commercial approaches that combine capacity building with targeted distribution partnerships.

In Asia-Pacific, growth in clinician training, increased awareness of long-acting contraceptive benefits, and expansion of outpatient care models are notable. Diverse regulatory environments and variations in public procurement mechanisms mean manufacturers often pursue country-specific strategies that address local reimbursement practices and cultural considerations regarding family planning. Across all regions, the interplay between urbanization, digital health adoption, and provider training programs is reshaping how devices are recommended, procured, and supported clinically, making regional customization a necessary component of effective market engagement.

A strategic overview of competitive positioning showing how clinical evidence, provider enablement, and distribution partnerships shape long-term leadership in the intrauterine device sector

Competitive dynamics among leading device makers and emerging challengers are increasingly defined by clinical differentiation, distribution agility, and investments in evidence generation. Firms that pair clear clinical advantages with robust post-market data and strong provider support programs generally achieve deeper integration into care pathways. Strategic alliances with pharmacies, hospital systems, and training consortia strengthen adoption by addressing practical barriers related to insertion competency, inventory management, and patient follow-up.

New entrants and niche players are focusing on distinct value propositions such as simplified insertion systems, reduced hormone exposure profiles, or novel materials designed to enhance tolerability. Established manufacturers respond by broadening educational outreach, expanding clinician training programs, and leveraging real-world data to substantiate safety and patient satisfaction claims. The competitive landscape therefore rewards a balanced approach that combines product-level innovation with meaningful investments in provider enablement and supply chain robustness.

Partnership models that integrate manufacturers with distribution networks and clinical training providers create durable advantages, particularly when they reduce time-to-provision for immediate postpartum insertions and outpatient procedures. Intellectual property portfolios remain relevant but are only one element of competitiveness; the ability to demonstrate consistent quality, regulatory compliance, and post-market vigilance increasingly determines long-term positioning. Companies that proactively manage lifecycle planning, clinician engagement, and evidence synthesis will be best placed to influence standard-of-care decisions and to sustain clinician and patient trust.

Actionable and high-impact recommendations for manufacturers and stakeholders to strengthen supply resilience, evidence generation, clinician training, and patient access across channels

Industry leaders should prioritize a set of pragmatic, high-impact actions to preserve access, protect clinical trust, and create differentiated value propositions. First, enhance supply chain resilience by diversifying component sourcing and by establishing validated contingency suppliers to mitigate tariff-related disruptions and other interruptions. This operational flexibility should be complemented by a clear regulatory roadmap for qualifying alternative manufacturing sites and materials to avoid clinical supply gaps.

Second, invest in robust post-market evidence programs that emphasize safety, patient-reported outcomes, and real-world performance across diverse populations and care settings. Such evidence supports clinical adoption, informs payer conversations, and strengthens brand credibility. Third, accelerate clinician training initiatives with a focus on immediate postpartum insertion, adolescent care, and outpatient insertion protocols; training should be modular, accessible, and tied to competency validation to ensure consistent clinical outcomes.

Fourth, align distribution strategies with evolving patient access models by combining traditional hospital pharmacy channels with online pharmacy engagement and targeted retail pharmacy partnerships. Ensure that patient counseling materials and digital tools are consistent across channels to reduce confusion and to protect continuity of care. Finally, adopt transparent pricing and contracting approaches that allow purchasers to plan around tariff volatility and that facilitate long-term supply agreements. Executing these recommendations will require cross-functional coordination between clinical affairs, regulatory, supply chain, and commercial teams, but will materially strengthen market position and patient access.

A transparent explanation of research sources, evidence triangulation, and methodological steps used to synthesize clinical, regulatory, and supply chain insights for intrauterine devices

This analysis is grounded in a multi-source research approach that synthesizes peer-reviewed clinical literature, regulatory filings, device labeling, expert clinician interviews, and a systematic review of supply chain and policy developments. Clinical insights derive from randomized trials, observational cohorts, and longitudinal safety registries, which were evaluated for methodological rigor and relevance to contemporary practice. Regulatory materials, including approvals and post-market surveillance summaries, were examined to identify emerging compliance trends and safety signals that affect product life-cycle management.

Commercial and operational conclusions are informed by structured interviews with clinicians, procurement leaders, and distribution partners, as well as by a thematic review of publicly available guidance on procurement and insertion protocols. Trade policy and tariff impacts were analyzed through a combination of import/export databases, customs classifications, and industry-reported responses to tariff changes, with attention to operational mitigations and supply chain realignment strategies. The research also incorporated an assessment of clinician training program design and digital engagement models to evaluate how these elements influence uptake and sustained use.

Throughout the analysis, findings were triangulated across multiple sources to ensure consistency, and limitations were explicitly documented, including potential regional data gaps and variability in service delivery models. Where uncertainties exist, the report highlights areas that would benefit from primary data collection or targeted market testing to validate strategic assumptions.

A concise conclusion synthesizing how clinical advances, supply resilience, and targeted market strategies collectively determine future intrauterine device accessibility and positioning

The intrauterine device landscape is at an inflection point where clinical innovation, changing care delivery models, and trade policy considerations converge to create both opportunity and complexity. Technological refinements and expanding clinical acceptance, particularly for immediate postpartum and adolescent insertion, are increasing the role of these devices in comprehensive reproductive health strategies. At the same time, supply chain sensitivity to tariffs and component sourcing underscores the need for operational agility and closer alignment between manufacturing, regulatory, and procurement functions.

Successful stakeholders will be those that build resilient supply networks, invest in rigorous post-market evidence, and deploy targeted clinician training while embracing modern patient access channels. Regional heterogeneity requires tailored approaches that reflect local regulatory environments and payer structures, and segmentation by device type, distribution channel, end user, and usage duration offers a practical blueprint for matching product attributes to patient and provider needs.

In conclusion, the next phase of intrauterine device evolution will reward enterprises that combine clinical credibility with operational excellence and that adopt transparent, patient-centered access strategies. By executing on the recommendations outlined in this summary, organizations can strengthen their positioning and contribute to expanded, equitable access to effective long-acting contraception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intrauterine Devices Market, by Device Type

  • 8.1. Copper
  • 8.2. Hormonal

9. Intrauterine Devices Market, by Usage Duration

  • 9.1. Over Five Years
  • 9.2. Three To Five Years
  • 9.3. Under Three Years

10. Intrauterine Devices Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Intrauterine Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Intrauterine Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intrauterine Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intrauterine Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Intrauterine Devices Market

16. China Intrauterine Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Bayer AG
  • 17.7. BioFem Therapeutics, LLC
  • 17.8. Chongqing Zhifei Biological Products Co., Ltd.
  • 17.9. CooperCompanies, Inc.
  • 17.10. Gedeon Richter Plc.
  • 17.11. Medicines360, Inc.
  • 17.12. Meril Life Sciences Pvt. Ltd.
  • 17.13. Mona Lisa N.V.
  • 17.14. Mylan NV by Viatris Inc.
  • 17.15. Novartis AG
  • 17.16. Ocon Medical Ltd
  • 17.17. Pregna International Ltd.
  • 17.18. Prosan International BV
  • 17.19. Searchlight Pharma Inc.
  • 17.20. Shenzhen Salubris Pharmaceuticals Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAUTERINE DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRAUTERINE DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COPPER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COPPER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COPPER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY OVER FIVE YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY OVER FIVE YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY OVER FIVE YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY THREE TO FIVE YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY THREE TO FIVE YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY THREE TO FIVE YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY UNDER THREE YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY UNDER THREE YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY UNDER THREE YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GCC INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 89. GCC INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GCC INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. G7 INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 104. G7 INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. G7 INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NATO INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 109. NATO INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NATO INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)